Maertens reported that caspofungin produced a 41% response rate when used as salvage therapy for invasive aspergillosis which had failed to response to standard treatment.

Klapholz and Pursell have published reviews of aspergillosis in AIDS.

Keating reported that aspergillosis has become more common among people with HIV at one London centre. They reported on 12 cases, 11 of which occurred during 1993. In every case specific risk factors were present, such as the presence of lymphoma or neutropenia induced by chemotherapy for KS or broad-spectrum antibiotics. 11 of the 12 had a CD4 count below 50.

Denning (1990) reported that the addition of flucytosine or rifampicin to intravenous amphotericin B (1.0 to 1.5 mg/kg) did not offer any survival benefit.

Denning (1994) treated 76 people with invasive aspergillosis with itraconazole (600 mg/day for 4 days followed by 400 mg/day) for a median of 46 weeks. 36% of participants had a complete or partial response, 4% were stable and 56% failed therapy or withdrew.

Kauffman treated 80 patients with itraconazole; 65% patients responded to treatment after three months.